Trial Profile
A Single-center, Phase 1 Dose Escalation Study of Trametinib Combined With HDM201 in Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Siremadlin (Primary) ; Trametinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms TRAHD
- 12 Sep 2023 Status changed from recruiting to completed.
- 15 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 22 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.